Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAM2029 in Symptomatic Polycystic Liver Disease
NCT05281328Phase 3Active, not recruiting
- Sponsor
- Camurus
- Start
- Jun 2022
- Primary completion
- Feb 2025
- Modality
- Peptides
- Countries
- 4
01
Overview
A Phase 3 trial of octreotide hydrochloride in Polycystic liver disease (PLD), sponsored by Camurus. Started Jun 2022; status: active, not recruiting.
02
Drugs
octreotide hydrochloride
03
Conditions
Polycystic liver disease (PLD)
Beyond the preview
Go deeper on NCT05281328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281328.